New and forthcoming anti-epileptic drugs

Current Opinion in Neurology

Volumn 24, Issue 2, 2011, Pages 159-164

  Prunetti, Paolo ^a   Perucca, Emilio ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

clinical trials; epilepsy; new anti epileptic drugs

Indexed keywords

ANTICONVULSIVE AGENT; BGG 492; BRIVARACETAM; CARBAMAZEPINE; CARISBAMATE; CLOBAZAM; DEOXYGLUCOSE; ESLICARBAZEPINE ACETATE; ETIRACETAM; GANAXOLONE; HARKOSERIDE; HUPERZINE A; ICA 105665; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PLACEBO; RETIGABINE; RUFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; STIRIPENTOL; T 2007; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VALROCEMIDE; YPP 3089;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BLURRED VISION; BRADYCARDIA; COORDINATION DISORDER; COST EFFECTIVENESS ANALYSIS; DIPLOPIA; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; FOLLOW UP; HEART FIBRILLATION; HUMAN; HYPONATREMIA; LENNOX GASTAUT SYNDROME; MYOCLONUS EPILEPSY; NAUSEA; NONHUMAN; PARTIAL ONSET SEIZURE; PR PROLONGATION; QT PROLONGATION; QUALITY OF LIFE; SEIZURE; SOMNOLENCE; TONIC CLONIC SEIZURE; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

ACETAMIDES; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DIOXOLANES; DRUG APPROVAL; DRUG DISCOVERY; EPILEPSY; HUMANS; REMISSION INDUCTION; TRIAZOLES;

EID: 79953031818     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834479a7     Document Type: Article

References (49)

1. Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures. Ther Clin Risk Manag 2010;6:103-109.
2. Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-463.
3. Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-287.
4. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010;89:278-285.
5. Halasz P, Cramer JA, Hodoba D, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010;51:1963-1969.
6. Nunes T, Sicard E, Almeida L, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010;26:1355-1362.
7. Vaz-da-SilvaM, Almeida L, FalcaoA, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther 2010;32:179-192.
8. Milovan D, Almeida L, Romach MK, et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav 2010;18:366-373.
9. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009;23:555-568.
10. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009;5:757-766.
11. Wang Y, Brittain JM, Jarecki BW, et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein 2 identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem 2010;285:25296-25307.
12. Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010;11:1595-1602.
13. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Phar macol 2010;50:459-471.
14. Sake JK, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1055-1068.
15. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-967.
16. Krauss G, Ben-Menachem E, Mameniskiene R, et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010;51:951-957.
17. Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by nonparenteral lacosamide. Epilepsia 2010;51:316-317.
18. Koubeissi MZ, Mayor CL, Estephan B, et al. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand 2011;123:142-146.
19. Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011;123:137-141.
20. WehnerT, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16:423-425.
21. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011;20:20-23.
22. Cuzzola A, Ferlazzo E, Italiano D, et al. Does lacosamide aggravate Lennox-Gastaut syndrome? Report of three consecutive cases. Epilepsy Behav 2010;19:650-651.
23. Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010;18:322-324.
24. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-1958.
25. Kluger G, Glauser T, KraussG, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122:202-208.
26. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics 2010;28:185-199.
27. Coppola G, Grosso S, Franzoni E, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol 2010;18:246-251.
28. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17:546-548.
29. Vendrame M, LoddenkemperT, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010;43:155-158.
30. Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24:1520-1525.
31. Elger CE, Stefan H, Mann A, et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-263.
32. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50:1899-1909.
33. KassäB, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008;49:343-348.
34. Chiron C. Stiripentol. Neurotherapeutics 2007, 4, 123-125. (Pubitemid 46127461)
35. Fisher JL. The anticonvulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009;56:190-197.
36. Luszczki JJ, Trojnar MK, Ratnaraj N, et al. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res 2010;90:188-198.
37. Inoue Y, OhtsukaY, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009;50:2362-2368.
38. An open-label study of add-on stiripentol in 25 Japanese patients, mostly children, with SMEI.
39. Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54.
40. French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75:519-525.
41. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89-124.
42. Faught E, Holmes GL, Rosenfeld WE, et al. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology 2008;71:1586-1593.
43. Sperling MR, Greenspan A, Cramer JA, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia 2010;51:333-343.
44. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43.
45. Czuczwar P, Wojtak A, Cioczek-Czuczwar A, et al. Retigabine: the newer potential antiepileptic drug. Pharmacol Rep 2010;62:211-219.
46. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-1204. (Pubitemid 46608467)
47. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine/(retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-1824.
48. Reddy DS, Rogawski MA. Ganaxolone suppression of behavioral and elec-trographic seizures in the mouse amygdala kindling model. Epilepsy Res 2010;89:254-260.
49. Mares P, Kubova H, Kasal A. Anticonvulsant action of a new analogue of allopregnanolone in immature rats. Physiol Res 2010;59:305-308.